SARS-CoV-2-specific immune responses after COVID-19 vaccination in end-stage renal disease patients and kidney transplant recipients

Conditions

Healthy volunteers, patients with end-stage renal disease on hemodialysis, peritoneal dialysis, or receiving kidney transplantation. ESRD kidney transplant SARS-CoV-2 quantiferon humoral immunity

Jackrapong Bruminhent, Chavachol Setthaudom, Rungthiwa Kitpermkiat, Sasisopin Kiertiburanakul, Kumthorn Malathum et al. (13 authors)

Scientific Reports2022-03-0422 citations

10.1038/s41598-022-07574-w

Short-Term Immunogenicity Profiles and Predictors for Suboptimal Immune Responses in Patients with End-Stage Kidney Disease Immunized with Inactivated SARS-CoV-2 Vaccine.

Boongird S, Chuengsaman P, Setthaudom C, Nongnuch A, Assanatham M, Phanprasert S, Kitpermkiat R, Kiertiburanakul S, Malathum K, Phuphuakrat A, Davenport A, Bruminhent J.

2021-12-0313 citations

10.1007/s40121-021-00574-9

SARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study)

Jackrapong Bruminhent, Chavachol Setthaudom, Pongsathon Chaumdee, Sarinya Boongird, Sasisopin Kiertiburanakul et al. (13 authors)

American Journal of Transplantation2021-10-1928 citations

10.1111/ajt.16867

Interventions

Those are volunteer who are healthy without co-morbidities.,ESRD patients who have been peritoneal dialysis,ESRD patients who have been hemodialysis,Kidney transplant recipients

Prevention,Prevention,Prevention,Prevention

Control group,Peritoneal dialysis group,Hemodialysis group,Kidney transplant group

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Healthy subjects, ESRD patients, or kidney transplant recipients who are willing to participate in the project.

Exclusion criteria

Exclusion criteria: Those who received the COVID-19 vaccine prior to

Design outcomes

Primary

Measure	Time frame
SARS-CoV-2-specific immunity at day 28 and 56 Neutralizing antibody test, Quantiferon SARS-CoV-2	—

Secondary

Measure	Time frame
COVID-19 within 6 months after vaccination SARS-CoV-2 RT-PCR	—

Countries

Thailand

Contacts

Public ContactJackrapong Bruminhent

Faculty of Medicine Ramathibodi Hospital, Mahidol University

jackrapong.brm@mahidol.ac.th6622011851

Outcome results

None listed